Clinical Research Directory
Browse clinical research sites, groups, and studies.
Palliative Thoracic ImmunoRT
Sponsor: University Health Network, Toronto
Summary
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Official title: Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
12
Start Date
2018-10-03
Completion Date
2027-09
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
Radiation combined with immunotherapy
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Locations (1)
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada